Phase 4 N=15 Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis
Synkinesis
Primary: Change in Sunnybrook Facial Grading System (SFGS) Between Baseline and 4 Month Scoring — 0.29; 5.86 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=71 Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis
Facial Nerve Injuries · Facial Paresis Associated With Facial Nerve Dysfunction · Facial Asymmetry
Primary: Change in Synkinesis Assessment Questionnaire (SAQ) Scores — 45.9; 38.8; 51.3; 45.2 units on a scale
N/A N=10 Synchronized Brain and Hand Stimulation After Stroke
Stroke · Upper Extremity Paresis
Primary: Percent Change in Box and Block Test — 20 percent change of number of blocks — p=.04
N/A N=14 Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
Stroke
Primary: Fugl-Meyer Upper Extremity Assessment Part A — 4.13; 5.38; 0.88 score on a scale — p=<0.0001
N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score
N/A N=75 Investigating the Effects of Rhythm and Entrainment on Fluency in People With Aphasia
Aphasia · Apraxia of Speech
Primary: Percent Syllables Correct — 99.22; 64.26; 99.46; 52.71 percentage — p=0.077
Phase 3 N=187 Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Sialorrhea
Primary: Occurrence, Seriousness, Severity, and Causality Assessment of Treatment Emergent Adverse Events (TEAE) — 7; 14; 3; 2 participants
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
Phase 3 N=187 Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Sialorrhea
Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001
N/A N=20 Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device
Deglutition Disorders
Primary: Pressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter. — 162.04; 129.66; 200.90; 170.66 mmHg — p=< 0.05
Phase 4 N=65 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
Blepharospasm
Primary: Change From Baseline to Week 4 in Blepharospasm Disability Index — -2.8; -1.3 Points on Scale
N/A N=23 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity
Upper Extremity Spasticity · Stroke · Acquired Brain Injury
Primary: Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O) — 1.52; 1.79 units on a scale